• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

The Importance of Imaging and Centralized Review in Clinical Trials


Imaging is an integral part of many clinical studies, particularly in the fields of oncology and ophthalmology. Learn why imaging and centralized review are essential for clinical trials, how to address challenges that arise in these studies, and the advantages of partnering with MERIT in this video.

  • Imaging provides an unbiased, structural assessment of many disease states, which is a complement to functional outcome measures
  • Centralized imaging review is particularly important in Phase II and III trials where multiple imaging sites are involved
  • Centralized imaging challenges can be mitigated with 1) imaging expertise, 2) standardization through certified QMS, and 3) an integrated technology platform
Related Videos
Jason Tate, FSP Talent Strategy Lead, PPD, part of Thermo Fisher Scientific
Corevitas Clinical Trials